SL Science Holding Ltd(SLBT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 59.54% | Shs Outstand | 560.8M | Perf Week | -15.48% |
| Market Cap | 0.73B | Forward P/E | - | EPS next Y | - | Insider Trans | 1.38% | Shs Float | 226.9M | Perf Month | -21.08% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 0.11% | Short Float | 0.02% | Perf Quarter | -58.01% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 114.24% | Short Ratio | 0.66 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.05M | Perf YTD | -67.25% |
| Book/sh | - | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | -90.97% ($14.50) | Perf Year | - |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 0% ($1.31) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.56% 8.81% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | 27.44 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | -16.32% ($1.57) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -36.86% ($2.07) | Rel Volume | 0.41 | Prev Close | $1.45 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -54.99% ($2.91) | Avg Volume(3M) | 0.08M | Price | $1.31 |
| IPO | 2026/6/15 | Option/Short | No/Yes | Trades | 172 | Volume | 32,193 | Change | -9.66% |
🧬 This biotech company, headquartered in Taipei, Taiwan, is listed on NASDAQ and is engaged in two key areas: skincare products based on exosomes and plant extracts, and cell therapy research focused on gamma-delta T cells. The company generates revenue from its cosmetics business while simultaneously advancing a cell therapy pipeline targeting solid tumors.
Over the past 1 year, on the lower side
91% below its 1-year high.
Traded less than usual. That is 41% of its average volume.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.1%.
Tap to view numbers
It ranks #178 of 594 in the industry
Based on market cap of $735M.
PHAR#177 Pharming Group NV ADR $755M PER 85.8 SLBT#178 SL Science Holding Ltd $735M PER - 
GERN#179 Geron Corp $726M PER - 
ANNX#180 Annexon Inc $722M PER - 
SANA#181 Sana Biotechnology Inc $709M PER - 
FAQ
What kind of company is SLBT?
SLBT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SLBT?
The market cap of SLBT is approximately $735M, ranking 2,824 within its sector.
What is the 52-week high and low for SLBT?
SLBT has recorded a 52-week high of $14.50 and a low of $1.31.
